@article {248,
	title = {Drug Review: Vonoprazan},
	journal = {PTB Reports},
	volume = {9},
	year = {2023},
	month = {December 2023},
	pages = {71-72},
	type = {Drug Review},
	chapter = {71},
	abstract = {<p class="rtejustify">Registrations: It had been registered in the following countries: United States of America (USA), United Kingdom (UK), Canada, and Saudi Arabia (SA.) USA, and Japan. Trade name (USA); VOQUEZNA Registration number (SA); Not available. Insurance Drug Formulary (SA); Not available. General Information: Registered Company: Pathom Pharmaceutics. Regulatory Status: RX. Mechanism of Action: Vonoprazan Potassium-competitive acid blocker (PCAB); inhibition in a potassiumcompetitive manner the H+, K+-ATPase enzyme system. Ampicillin derivative penicillin-binding proteins and cell wall inhibitor. Clarithromycin reversibly binds to the P site of 50S ribosomal subunit as macrolide antimicrobial; and inhibits RNA-dependent protein synthesis by stimulating the peptidyl t-RNA dissociation from ribosomes.\&nbsp;<strong> Read more...</strong></p>
},
	doi = {10.5530/PTB.2023.9.12},
	author = {Juman Alsaab}
}
